People with type 2 diabetes have too much sugar in their blood and need treatment to control their sugar level. The 3 study compounds in this study are similar to an approved antidiabetic medicine that helps to lower blood sugar levels in people with type 2 diabetes. This approved antidiabetic medicine is generally safe and well tolerated. The study compounds are expected to have the same antidiabetic effect as the approved medicine. The purpose of this study is to investigate how quickly and to what extent each of the 3 study compounds are broken down in the body (this is called pharmacokinetics). The dose of each study compound will be very low (this is called a microdose), and will be labelled with a small amount of carbon-14. This is radioactive, and it makes it possible to track the study compound in the blood. The 3 study compounds in this study have not been given to humans before. The study will be performed in up to 18 healthy male volunteers. The study will consist of 3 groups of 6 volunteers each. Each participant will receive only one dose of study medicine.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
Novo Nordisk Investigational Site
Groningen, Netherlands
The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compounds
hours
Time frame: From time of first dosing (Day 1) until Day 64
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.